Phathom Pharmaceuticals (PHAT) Offers Eligible Patients VOQUEZNA for as Little as $0

Phathom Pharmaceuticals (PHAT) announced that eligible patients may pay as little as $0 for VOQUEZNA tablets through BlinkRx, with free home delivery and prior authorization support. The program is subject to eligibility requirements and benefit limits. Cash-pay options start at $55 per 30-day supply, with state-specific discounts in Massachusetts. No financial impact or revenue estimates were provided.

Original reporting
Published Nov 3, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 1:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Phathom Pharmaceuticals (PHAT) Offers Eligible Patients VOQUEZNA for as Little as $0 — source image
Decision brief

The 30-second read

$PHATNeutralLow
01

Why it matters

The announcement provides a new pricing pathway but lacks quantitative guidance, making the immediate market impact uncertain.

02

Market read

A modest, low‑impact commercial initiative that may slightly improve prescription rates without clear revenue implications.

03

What to watch

Potential administrative costs of the program and insurer reimbursement policies.

Relevance 4/10Novelty 3/10Timing: effective immediately

Background

Phathom Pharmaceuticals (PHAT) markets VOQUEZNA for gastro‑esophageal reflux disease (GERD). The company introduced a patient‑access program offering the drug at $0 for eligible insured patients, with a cash‑pay option for uninsured patients.

Company-level read

Ticker impact

$PHATNeutralMedium confidence
Context

Phathom Pharmaceuticals announced a program allowing eligible commercially insured patients to obtain VOQUEZNA at $0 out‑of‑pocket, a new commercial access initiative.

Expected impact

potential slight upside as cost barrier is removed, but limited by unknown uptake.

Evidence & confidence

Lower out‑of‑pocket cost may encourage prescriptions, yet no financial guidance or volume estimates are provided.

Market effects

May marginally improve outlook for GERD treatment segment.

Limited to U.S. commercial insurance market.

Low; impact confined to Phathom and its patients.

Counterpoint

Without clear uptake data, the program may not translate into meaningful sales.

Key entities

  • Phathom Pharmaceuticals

    U.S. biotech developing VOQUEZNA for GERD.

Related articles

$PHATMed

H.C. Wainwright reiterates Buy on Phathom stock, $26 target

H.C. Wainwright reiterated a Buy rating and $26 price target for Phathom Pharmaceuticals (PHAT), citing strong revenue growth and pipeline progress. The stock is up 8.36% weekly but down 62.5% year-to-date. Phathom reported Q3 2026 EPS of $0.04, beating estimates, but revenue missed slightly. The company is focused on VOQUEZNA's commercial execution and regulatory exclusivity.

$PHATMed

Phathom Pharmaceuticals Inc (PHAT) (Q3 2026) Earnings Call Highlights: Second

Phathom Pharmaceuticals (PHAT) reported stable commercial insurance coverage and no expected changes from a second PCAB entrant. Gross margin decline was due to a one-time manufacturing charge. Q4 revenue growth may reach the upper half of guidance due to momentum and Medicare Part D coverage. Phase 2 EOE trial data will be reported this quarter, with pediatric exclusivity discussions in 2027. 2027 revenue is expected to grow faster than operating expenses, driving positive cash flow.

$PHATMed

What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call

Phathom Pharmaceuticals (PHAT) reported Q3 gross profit margin of 78%, below guidance due to one-time charges. The company expects full-year 2026 gross-to-net discount toward the lower end of its 55%-59% range and maintains cash operating expense guidance of $235M-$245M. Phathom anticipates top-line data from its Phase II pHalcon-EoE study in Q4 and plans to discuss a Phase III program with the FDA in 2027 if results support further development.

$PHATMed

Phathom Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary

Phathom Pharmaceuticals reported Q3 2026 revenue of $84.7M, up 71% YoY, and maintained positive cash flow. The company launched 'Access First' to improve prescription adoption and introduced a $0 copay program. It reiterated FY2026 revenue guidance of $310M-$325M and expects durable positive cash flow in 2027. Phase II data for EoE is anticipated in Q4 2026.

$PHATMed

Phathom (PHAT) Q3 2026 Earnings Call Transcript

Phathom (PHAT) reported Q3 2026 net revenues of $84.7M, operating profit of $5.8M, and cash from operations of $2.1M. The company highlighted strong prescription growth for VOQUEZNA, with 2M+ prescriptions filled since launch. Phathom reiterated its full-year revenue guidance of $310M-$325M and discussed legal action by BDR Pharmaceuticals challenging VOQUEZNA's exclusivity period.